<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799939</url>
  </required_header>
  <id_info>
    <org_study_id>305/2018</org_study_id>
    <nct_id>NCT03799939</nct_id>
  </id_info>
  <brief_title>Chimney Trial of Parastomal Hernia Prevention</brief_title>
  <official_title>Chimney Trial - Randomized, Controlled, Multi Center Trial of Parastomal Hernia Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chimney trial is designed to compare the effectiveness and safety of specifically designated
      polyvinylidene fluoride mesh (PVDF, Dynamesh IPST) to controls in a multi center, randomized
      setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The European Hernia Society recommends the use of prophylactic mesh when permanent colostomy
      is made. The results of previous trials using keyhole technique are partially unsatisfactory.
      Specifically designed PVDF mesh used in this trial showed promising results in previous small
      trial.

      Chimney trial is designed to compare the effectiveness and safety of mesh group to controls
      operated with no preventive mesh in parastomal hernia prevention after laparoscopic or
      robotic-assisted abdominoperineal resection or low Haartman's procedure for rectal
      adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Chimney trial is a prospective randomized controlled multicenter trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants are unaware of the randomization group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of parastomal hernia</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of parastomal hernia at 12 months follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of parastomal hernia at long term follow up</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of parastomal hernia during 5 years of follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection rate</measure>
    <time_frame>30 days</time_frame>
    <description>Surgical site infections measured by Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Complications measured by Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stoma related complications</measure>
    <time_frame>5 years</time_frame>
    <description>Stoma related complications measured by Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>5 years</time_frame>
    <description>Need for reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>1 day</time_frame>
    <description>Operative time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay at the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rand 36 quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life measured by Rand-36 quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by Colostomy impact score</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life measured by Colostomy impact score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic substudy</measure>
    <time_frame>5 years</time_frame>
    <description>Medico-economic substudy including both short and long term costs included in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological substudy of stoma distance</measure>
    <time_frame>3 years</time_frame>
    <description>Distance of stoma from midline defined by umbilicus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological substudy of adipose tissue thickness</measure>
    <time_frame>3 years</time_frame>
    <description>Thickness of adipose tissue on computer tomography scan on contralateral site of stoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Parastomal Hernia</condition>
  <condition>Rectal Adenocarcinoma</condition>
  <condition>Abdominoperineal Resection</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in control group are operated with no preventive mesh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intervention group</intervention_name>
    <description>Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Rectal adenocarcinoma with curative intent laparoscopic or robotic assisted
             abdominoperineal resection or low Hartmann´s operation and permanent colostomy

          -  Patient has a life expectancy of at least 12 months.

          -  Patient must sign Informed consent before any study procedures and agrees to attend
             all study visits

        Exclusion Criteria:

          -  Abdominoperineal resection or Hartmann's operation by laparotomy or conversion to
             laparotomy

          -  Complication requiring laparotomy during post surgery treatment at surgical ward after
             APR

          -  Patient with a comorbid illness or condition that would preclude the use of surgery
             (ASA 4-5).

          -  Patients with concurrent or previous malignant tumors within 5 years before study
             enrollment

          -  Patients with T4b tumors which impose a multi-organ resection

          -  Rectal malignancy other than adenocarcinoma

          -  Patient undergoing emergency procedures

          -  Planned rectal surgery along with major concomitant procedures (e.g. hepatectomies,
             other intestinal resections).

          -  Metastatic disease with no possibility of curative surgery

          -  Pregnant or suspected pregnancy

          -  Patients living geographically distant and/or unwilling to return for follow-ups or
             comply with all study requirements

          -  Active abdominal infection at the time of surgery

          -  Previous surgery at the colostomy site

          -  Language barrier or other reasons why informed consent is not possible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Mäkäräinen-Uhlbäck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Mäkäräinen-Uhlbäck, M.D.</last_name>
    <phone>+358505794011</phone>
    <email>elisa.makarainen-uhlback@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tero Rautio, Ph.D.</last_name>
    <phone>+35883152817</phone>
    <email>tero.rautio@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Carpelan-Holmström, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keski-Suomi Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matti Kairaluoma, Ph.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Anu Ehrlich, Ph.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Mäkäräinen-Uhlbäck, M.D.</last_name>
      <phone>+358505794011</phone>
      <email>elisa.makarainen-uhlback@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarja Pinta, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsi Lehto, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Karvonen, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maziar Nikberg</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maziar Nikberg, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 6, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Elisa Makarainen-Uhlback</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

